UnitedHealth Group Incorporated (UNH) Q2 FY2026

Business

From the FY2025 10-K, accession 0000731766-26-000062.

UnitedHealth Group is a U.S. health care company with two linked businesses: UnitedHealthcare, which sells health benefits (insurance and benefit administration) to employers, individuals, Medicare beneficiaries and state Medicaid programs, and Optum, which delivers care, sells health-care data, technology and services, and runs a pharmacy benefit manager. Most of its revenue is premiums: of 2025 total revenues of $447.6 billion, premiums were $352.2 billion, products (mainly pharmaceuticals dispensed by Optum Rx) $53.4 billion, services $38.0 billion and investment and other income $3.9 billion. The 10-K states that premium revenues from risk-based products make up nearly 80% of consolidated revenues, and that premium revenues from CMS (the federal Medicare and Medicaid agency) were 44% of total 2025 revenues, most of it in UnitedHealthcare Medicare & Retirement. The businesses participate primarily in U.S. health markets, and the company is exiting its remaining South American operations.

There are four reportable segments: UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. Optum earns a large share of its revenue from UnitedHealthcare, which is eliminated on consolidation: in 2025, UnitedHealthcare reported $344.9 billion and Optum $270.6 billion of segment revenue, against consolidated revenue of $447.6 billion after $168.0 billion of eliminations.

UnitedHealthcare (2025 revenue $344.9 billion; 49.76 million medical members at December 31, 2025) has three businesses:

• Employer & Individual ($79.2 billion revenue), risk-based plans, where it takes on medical cost in exchange for a fixed premium, and fee-based administrative services for employers that self-fund. It served 29.7 million people at year-end 2025, of whom 21.5 million were fee-based and 8.2 million risk-based.
• Medicare & Retirement ($171.3 billion revenue), Medicare Advantage (8.4 million people), Medicare Part D (10.4 million, including 2.8 million in stand-alone plans) and Medicare Supplement (4.3 million). Medicare Advantage is paid as a fixed monthly per-member premium from CMS, adjusted for geography, demographics and each member's health status (risk adjustment).
• Community & State ($94.4 billion revenue), Medicaid, CHIP, dual-eligible special needs plans and long-term services programs in 32 states and the District of Columbia, serving nearly 7.4 million people.

Optum Health (2025 revenue $102.0 billion) delivers primary, specialty, surgical, in-home, behavioral and virtual care. Its main model is fully accountable value-based care: Optum Health takes responsibility for patients' total health-care costs in exchange for a monthly premium. It also earns administrative fees and fee-for-service revenue. It served about 95 million consumers at year-end 2025, down from 100 million.

Optum Insight (2025 revenue $19.4 billion) sells data, analytics, technology, revenue-cycle, payment-integrity and managed services to hospitals, physicians, health plans, state governments and life-sciences companies. Contracts often run for several years: the backlog was about $31.1 billion at December 31, 2025, of which $18.3 billion is expected within 12 months and $12.9 billion is with affiliates.

Optum Rx (2025 revenue $154.7 billion) is the pharmacy benefit manager and pharmacy services business. It has a network of about 64,000 retail pharmacies and runs home-delivery, specialty, community-health and infusion pharmacies. In 2025 it managed $188 billion of pharmaceutical spending, including nearly $87 billion of specialty drugs, and filled 1,659 million adjusted scripts.

2026 realignment. On January 1, 2026, Optum Financial (including Optum Bank) moved from Optum Health to Optum Insight, and prior periods are recast to match. At year-end 2025 Optum Financial had nearly 26 million consumer accounts and more than $27 billion of assets under management. The four reportable segments did not change.

The company had more than 390,000 employees at December 31, 2025, of whom nearly 165,000 were clinical professionals. Stephen Hemsley has been Chair and CEO since May 2025, and Wayne DeVeydt has been CFO since September 2025.

Risk factors

From the FY2025 10-K, accession 0000731766-26-000062 (Item 1A). The Q2 2026 10-Q reports no material changes to these risk factors.

• Medical cost estimation and pricing. Premiums are set in advance for a fixed period, so costs above forecast usually cannot be recovered until the next pricing cycle. The 10-K lists the drivers: unit-cost inflation, higher utilization, provider billing intensity, new and costly drugs, and changes in the member mix. This risk materialized in 2025, when the company says its pricing and member health-status assumptions fell "well-short" of medical cost trends. Reserves for claims incurred but not yet reported also depend on judgment: a 1% error in year-end 2025 medical costs payable would move 2025 net earnings by about $300 million.
• Dependence on government programs. Medicare Advantage rate notices have set industry base rates below forward medical cost trend for several years. CMS's revisions to the risk-adjustment model reduce funding, and CMS/OIG risk adjustment data validation (RADV) audits can lead to retroactive payment adjustments. Star ratings below four stars mean losing quality bonus payments. Medicaid rates lag the health status of members, and state contracts are periodically rebid. Part D auto-enrollment depends on bidding below regional benchmarks.
• Legal and regulatory exposure. The company is regularly subject to government investigations, audits and private litigation, including class actions and False Claims Act whistleblower suits. In the DOJ-backed whistleblower case over Medicare Advantage risk-adjustment submissions, a court-appointed Special Master recommended summary judgment for the company in March 2025, and the DOJ asked the court to reject that report in April 2025. The company says it cannot estimate the outcome. Pharmacy benefit management practices face investigations and proposed federal and state legislation on rebates, spread pricing, networks and formularies.
• Cybersecurity and data integrity. Change Healthcare suffered a cyberattack in 2024, and the 10-K uses it as an example of the risk of disruption, liability and reputational harm. Recently acquired or non-integrated businesses can carry greater vulnerabilities.
• Provider relationships and value-based care execution. Results depend on contracting with hospitals and physicians at competitive rates, on keeping relationships with employed and affiliated physicians, and on running fully accountable value-based arrangements profitably. Provider groups with strong market positions can weaken the company's bargaining power.
• Competition across every business, including from consolidation among competitors and suppliers and from new entrants with disruptive technology.
• Acquisitions and integration. The company makes acquisitions regularly. These carry antitrust risk, integration risk and exposure to the acquired businesses' past practices.
• Goodwill and intangibles carried at $131 billion, 42% of total assets, at December 31, 2025. Divestitures can trigger impairment and disposition charges.
• Holding-company structure. Cash for dividends, buybacks and debt service depends on dividends from regulated insurance subsidiaries, which need state approval above certain thresholds.
• Credit ratings. The company has been the subject of downgrades and other negative rating actions in past periods, and a downgrade would raise borrowing costs. Moody's, S&P and Fitch all had a negative outlook at June 30, 2026 (see Current quarter).
• Other named risks: the use of AI in operations; investment and loan portfolio losses; economic downturns reducing employer coverage and government budgets; the producer and broker distribution network; key-executive succession; public-health emergencies; and protection of proprietary data and software.

Management's discussion, fiscal 2025

From the FY2025 10-K, accession 0000731766-26-000062 (Item 7).

Results. 2025 revenues rose 12% to $447.6 billion. UnitedHealthcare grew 16% and Optum 7%, driven by more Medicare Advantage members, higher-acuity Medicaid members, growth at Optum Rx and pricing. Earnings from operations fell 41%:

Cash flows from operations were $19.7 billion in 2025.

Why margins fell. The medical care ratio rose 3.6 points. Management attributes this to Medicare funding reductions, elevated medical cost trend (higher care patterns, unit costs and service intensity), the profile of newly added value-based care patients, the early recognition of expected 2026 losses on certain Optum Health value-based contracts, less favorable reserve development (prior-year development was a favorable $140 million in 2025 against $700 million in 2024), the Inflation Reduction Act's redesign of Medicare Part D, and morbidity changes in the individual exchange market.

Segment earnings from operations, 2025 vs. 2024:

• UnitedHealthcare: $9.4 billion vs. $15.6 billion (margin 2.7% vs. 5.2%).
• Optum Health: a loss of $278 million vs. earnings of $7.8 billion, reflecting Medicare Advantage funding cuts, elevated cost trends, new-patient profile, restructuring (including the loss-contract reserve), and 2024 disposition gains not repeating.
• Optum Insight: $2.6 billion vs. $3.1 billion.
• Optum Rx: $7.2 billion vs. $5.8 billion. This includes a gain on deconsolidating a business.

Fourth-quarter 2025 actions. After a strategic review aimed at refocusing the business, including Optum Health's value-based care, the company booked:

• Portfolio actions: a net gain of $568 million. This was a $1.5 billion net gain at Optum Rx, including a $1.7 billion gain on deconsolidating a business after governance rights changed, offset by losses of $821 million at Optum Health and $68 million at Optum Insight. It also agreed to sell its remaining South American operations.
• Restructuring and other actions: $2.5 billion in total. This comprised $746 million for real-estate rationalization and workforce reductions, $573 million of contract reassessments, a $623 million loss-contract reserve for expected 2026 losses at certain value-based care businesses, $329 million of net equity-security valuation losses, and $250 million of advance funding to the United Health Foundation. By segment, it was mostly Optum Health ($1.7 billion).
• Change Healthcare cyberattack: a $799 million increase in reserves against collection of interest-free loans made to providers after the February 2024 attack, and other customer balances, at Optum Insight.

Outlook framed in the 10-K. Management expected Medicare Advantage membership, value-based care patient counts and Medicaid membership (reduced eligibility and an exit from one state) to shrink in 2026. It said the 2027 Medicare Advantage Advance Notice was "far below" the expected industry forward medical cost trend.

Balance sheet at year-end 2025. Cash, investments and marketable securities totaled $74.7 billion, including $24.4 billion of cash and cash equivalents, of which about $1.1 billion was available for general corporate use. Loan receivables, mainly at Optum Bank, were $9.7 billion. In 2025, the U.S. regulated subsidiaries received net capital infusions of $535 million from their parent companies; in 2024 they had paid net dividends of $9.2 billion.

Current quarter, Q2 2026 (three months ended June 30, 2026)

From the Q2 2026 10-Q, accession 0000731766-26-000197, unless marked as from the July 16, 2026 earnings release (Form 8-K, accession 0000731766-26-000191).

Headline results. Revenue was flat while earnings from operations rose 55%. The earnings release attributes the improvement to strong performance at both UnitedHealthcare and Optum. The 10-Q attributes the lower medical care ratio to favorable prior-period reserve development, affordability and medical cost management initiatives, and pricing.

The company's non-GAAP adjusted EPS (earnings release) adds back intangible amortization ($0.38 per share) and the net portfolio divestiture and South American impacts ($0.11), and deducts restructuring and other items ($0.06) and the tax effect of the adjustments ($0.09).

Medical costs. Medical costs fell 4%. Management attributes this to fewer people served at UnitedHealthcare and Optum Health and to favorable prior-period reserve development, partly offset by medical cost trend that remains above historical levels, including higher provider reimbursement under the No Surprises Act's independent dispute process and greater service and coding intensity in commercial business. For the six months, favorable prior-year development was $1.25 billion (against $320 million a year earlier), which the 10-Q attributes to a favorable respiratory illness season and other individually insignificant factors.

Segments, Q2 2026 vs. Q2 2025:

• UnitedHealthcare: revenue $86.0 billion (flat); earnings from operations $3.94 billion vs. $2.08 billion (margin 4.6% vs. 2.4%). Revenue fell as Medicare Advantage, risk-based commercial and Medicaid membership shrank and the company rebated individual exchange profits, offset by pricing and Medicaid rate increases. Earnings also benefited from favorable reserve development and cost management.
• Optum Health: revenue $23.5 billion (−5%) on fewer value-based care patients (about 700,000 fewer, per the earnings release) and dispositions; earnings from operations $1.19 billion vs. $429 million (margin 5.1% vs. 1.7%). The improvement came from cost management, more favorable reserve development and a $50 million net decrease in loss-contract reserves.
• Optum Insight: revenue $5.4 billion (+3%); earnings from operations $1.37 billion vs. $1.21 billion.
• Optum Rx: revenue $38.3 billion (flat); earnings from operations $1.49 billion vs. $1.44 billion. Adjusted scripts fell to 387 million from 414 million as UnitedHealthcare membership shrank.

Membership. UnitedHealthcare served 48.5 million people at June 30, 2026, 1.59 million fewer than a year earlier. The 10-Q attributes the decline to benefit design and pricing actions, reduced Medicaid eligibility and the exit from one state:

• Medicare Advantage: 7.57 million, down 785,000 year over year and down from 8.45 million at December 31, 2025.
• Medicaid: 6.78 million, down 710,000 on reduced eligibility and a one-state exit. The earnings release names the state as Louisiana.
• Risk-based commercial: 7.66 million, down 785,000.
• Fee-based commercial: 22.27 million, up 735,000.

Management expects Medicare Advantage and value-based care contraction to continue through 2026. The company has pledged to rebate its 2026 profits on individual exchange (ACA) products to customers.

Regulatory backdrop. The 2027 Medicare Advantage Final Notice moved toward expected industry cost trend but remains below it. On March 6, 2026, the IRS issued Notices of Proposed Adjustment covering intercompany transfer pricing with a foreign subsidiary for tax years 2017–2020. The IRS seeks to significantly increase taxable income for those years and could pursue later years too. The company disagrees, intends to contest, and believes its reserves for uncertain tax positions are adequate.

Portfolio and restructuring. Net portfolio divestitures produced a $39 million net loss in Q2 and a $191 million net gain for the six months. During the first half, the company sold businesses classified as held for sale at year-end 2025 for $1.1 billion in cash, a net gain of $211 million: a $525 million gain at Optum Insight and a $314 million incremental loss at Optum Health. It contributed $400 million of the Optum Insight proceeds to the United Health Foundation. The sale of the remaining South American operations is still expected to close in the second half of 2026.

Cash flow and capital.

• Cash flow: operating cash flow for the six months was $20.0 billion against $12.6 billion, driven by higher earnings, the timing of government payments, other favorable working capital and Inflation Reduction Act changes affecting pharmacy rebates.
• Debt: the company repaid $2.5 billion of long-term debt and had no commercial paper outstanding at June 30. The earnings release says it targets a debt-to-capital ratio of about 40% by year-end.
• Buybacks: in the first half the company repurchased about 10.5 million shares at an average of $344.08. This includes 6.4 million shares bought by a counterparty at $312.73 under $2.0 billion of forward contracts. Remaining Board authorization was 10.6 million shares.
• Dividend: raised in June 2026 to an annual rate of $9.28 per share ($2.32 quarterly), from $8.84.
• Credit ratings at June 30, 2026: Moody's A2, S&P A+ and Fitch A, all with negative outlook; A.M. Best A-, stable.

Guidance. With second-quarter results on July 16, 2026, the company raised its full-year 2026 outlook, citing year-to-date performance and an improved outlook for the rest of the year. By segment, it now expects operating earnings above $12.0 billion at UnitedHealthcare (up from above $10.8 billion), above $2.275 billion at Optum Health, above $4.925 billion at Optum Insight and above $6.25 billion at Optum Rx. It expects a tax rate of about 18.5%. Optum Health's reported guidance includes $405 million of operating earnings from the net change in loss-contract reserves, which is excluded from adjusted figures.

Subsequent events

From the Q2 2026 10-Q, accession 0000731766-26-000197 (Notes 6 and 7), and the 2026 earnings releases cited below.

• $3.0 billion acquisition closed, July 2, 2026. The 10-Q says that in the first quarter of 2026 the company agreed to acquire "a company in the health care sector" for $3.0 billion, and completed the acquisition on July 2, 2026. It paid $1.5 billion in cash, and the remaining $1.5 billion is payable within one year. The 10-Q does not name the target. The company's earnings releases (accessions 0000731766-26-000121 and 0000731766-26-000191) report that it agreed to acquire Alegeus Technologies, a benefits-administration platform for consumer-directed health-care accounts, during the first quarter of 2026, and that Optum Insight completed that acquisition on July 2, 2026. That is the same signing quarter and closing date as the $3.0 billion transaction.
• Forward share repurchase settled, July 1, 2026, $2.0 billion. The company paid the $2.0 billion liability for the 6.4 million shares the counterparty had bought under the forward repurchase contracts.
• South American divestiture still pending. The sale of the remaining South American operations, agreed in the fourth quarter of 2025, was still expected to close in the second half of 2026 as of the 10-Q filing.
• The 10-Q reports no other events after June 30, 2026, including no new borrowings or litigation outcomes.

Filings that contain financial statements

UnitedHealth Group furnishes condensed consolidated financial statements (statements of operations, balance sheets, statements of cash flows, plus supplemental financial information) in the Exhibit 99.1 earnings press releases attached to its Item 2.02 Forms 8-K:

• Form 8-K filed July 16, 2026, accession 0000731766-26-000191: second quarter 2026 (three and six months ended June 30, 2026).
• Form 8-K filed April 21, 2026, accession 0000731766-26-000121: first quarter 2026 (three months ended March 31, 2026).
• Form 8-K filed January 27, 2026, accession 0000731766-26-000025: fourth quarter and full year 2025.
• Form 8-K filed October 28, 2025, accession 0000731766-25-000301: third quarter 2025 (three and nine months ended September 30, 2025).

Earnings releases and guidance

• July 16, 2026 (second quarter 2026; 0000731766-26-000191). Revenues were $112.0 billion and earnings from operations were $8.0 billion. GAAP earnings were $6.04 per share and adjusted earnings were $6.38 per share. The medical care ratio was 86.7% (89.4% a year earlier), including $860 million of net favorable prior period development; the operating cost ratio was 12.7% (12.3%). Cash flows from operations were $11.1 billion, and the debt-to-capital ratio was 41.2%. UnitedHealthcare served 48.5 million people, down 525,000 sequentially. The company raised its 2026 outlook: adjusted earnings of $19.50 to $20.00 per share (from greater than $17.75 set January 27, 2026), GAAP earnings of $18.45 to $18.95 per share (from greater than $17.10), earnings from operations greater than $25,450 million (from greater than $24,000 million), a medical care ratio of 88.1% plus or minus 25 basis points (from 88.8% plus or minus 50), cash flows from operations of about $24.0 billion (from greater than $18.0 billion), and share repurchases of at least $5.0 billion (from about $2.5 billion). The company repurchased $4.0 billion of stock through mid-July 2026.
• April 21, 2026 (first quarter 2026; 0000731766-26-000121). Revenues were $111.7 billion, GAAP earnings were $6.90 per share and adjusted earnings were $7.23 per share. The medical care ratio was 83.9% and the operating cost ratio was 13.8%. Full year 2026 outlook was raised to GAAP earnings of greater than $17.35 per share and adjusted earnings of greater than $18.25 per share.
• January 27, 2026 (fourth quarter and full year 2025; 0000731766-26-000025). Full year 2025 revenues were $447.6 billion, GAAP earnings were $13.23 per share and adjusted earnings were $16.35 per share. A fourth quarter charge of $1.6 billion net of taxes ($1.78 per share) covered final cyberattack costs, net portfolio divestitures and restructuring, and was excluded from adjusted earnings. Initial 2026 outlook: revenues greater than $439.0 billion, earnings from operations greater than $24.0 billion, GAAP earnings greater than $17.10 per share and adjusted earnings greater than $17.75 per share.
• October 28, 2025 (third quarter 2025; 0000731766-25-000301). Revenues were $113.2 billion; GAAP earnings were $2.59 per share and adjusted earnings were $2.92 per share; the medical care ratio was 89.9%. The 2025 outlook was raised to GAAP earnings of at least $14.90 per share and adjusted earnings of at least $16.25 per share. The release states the Amedisys transaction closed on August 14, 2025.
• January 12, 2026 (0000731766-26-000020). Item 7.01: management intended to reaffirm, in investor meetings, the adjusted 2025 earnings per share expectations disclosed on October 28, 2025.
• September 9, 2025, Form 8-K/A (0000731766-25-000247). Item 7.01: management intended to reaffirm adjusted 2025 earnings per share expectations from July 29, 2025, which incorporated closing the Amedisys acquisition in August 2025 (expected to be dilutive to adjusted earnings per share), and estimated about 78% of Medicare Advantage membership in plans rated 4 stars or higher for Star Year 2026, based on preliminary CMS data.

M&A and portfolio changes

• Alegeus Technologies: signed in the first quarter of 2026, closed July 2, 2026. The April 21, 2026 release (0000731766-26-000121) states the company entered into an agreement to acquire Alegeus, a consumer-directed healthcare account platform, subject to regulatory review and expected to be earnings neutral to 2026. The July 16, 2026 release (0000731766-26-000191) states Optum Insight "completed its acquisition of Alegeus on July 2, 2026." The press releases give no purchase price.
• Optum UK sale: completed. The April 21, 2026 release states the company completed the sale of the Optum UK business, with $400 million in net proceeds committed to the United Health Foundation, and describes the company as refocused on U.S. health care and exiting non-U.S. businesses.
• Amedisys: closed August 14, 2025 (October 28, 2025 release, 0000731766-25-000301).

Capital actions

• April 21, 2026 release: the company entered into an arrangement to buy back at least $2 billion of its common stock, expected to be completed by the end of the second quarter 2026. The July 16, 2026 release raises the full year 2026 repurchase outlook to at least $5.0 billion.

Management and board

• February 25, 2026 (0000731766-26-000046), Item 5.02. On February 23, 2026 the Compensation and Human Resources Committee amended Stephen Hemsley's May 14, 2025 stock option to add a two-year holding requirement after the three-year cliff vesting; net shares from exercise must be held until May 14, 2030, except death or disability.
• March 2, 2026 (0000731766-26-000064), Item 5.02. Dennis Stankiewicz, Corporate Controller, was appointed Chief Accounting Officer effective March 2, 2026. Tom Roos, Chief Accounting Officer since August 2015, became Chief Financial Officer of Optum Insight.
• November 21, 2025 (0000731766-25-000314), Item 5.02. Scott Gottlieb, M.D., was appointed an independent director, announced November 18, 2025.
• June 5, 2026 (0000731766-26-000138), Item 5.07. At the June 1, 2026 annual meeting, all nine directors were elected, say-on-pay was approved (82.74% of votes for), Deloitte & Touche LLP was ratified as auditor for 2026, and a shareholder proposal for an independent board chair was not approved (20.24% for).
• November 13, 2025 (0000731766-25-000310), Item 5.03. Bylaws were amended, effective November 6, 2025, solely to reflect a change in the Delaware registered office and registered agent.

Routine investor-conference filings

Item 7.01 notices of conference appearances: UBS Global Healthcare Conference, November 10, 2025 (0000731766-25-000308); Barclays Global Healthcare Conference, March 10, 2026 (0000731766-26-000067); Bank of America Securities Health Care Conference, May 12, 2026 (0000731766-26-000129); Wells Fargo Healthcare Conference, September 9, 2026 (0000731766-26-000205). These carry no new financial information.

About this file

UNH annual income statement, balance sheet and cash flow

Taken from the SEC filings and normalized to actual dollars.

UNH quarterly income statement, balance sheet and cash flow

Taken from the SEC filings and normalized to actual dollars.

UNH year-to-date income statement and cash flow

Taken from the SEC filings and normalized to actual dollars.

UNH trailing twelve month income statement and cash flow

Derived by AI from the figures the filings report. No filing prints these, so none of them is linked.

• Derivation. Computed, not printed in either filing: full year 2025 from the FY2025 10-K (accession 0000731766-26-000062), plus the six months ended June 30, 2026, less the six months ended June 30, 2025, both from the Q2 2026 10-Q (accession 0000731766-26-000197).

Adjustments

Notes

• Sources: the three fiscal years (2023, 2024, 2025) and the December 31, 2025 and 2024 balance sheets come from the FY2025 Form 10-K (accession 0000731766-26-000062, filed March 2, 2026). The quarters ended June 30, 2026 and June 30, 2025, the six-month periods and the June 30, 2026 balance sheet come from the Q2 2026 Form 10-Q (accession 0000731766-26-000197, filed August 10, 2026).
• The 10-Q's December 31, 2025 balance sheet column matches the 10-K's balance sheet line for line.
• Line items follow the company's own statement captions. operating_income is the line the company labels "Earnings from operations". net_earnings_attributable_to_unitedhealth_group_common_shareholders is the figure earnings per share is based on; net_earnings includes the share belonging to noncontrolling interests.
• Signs follow the statements: interest expense, the provision for income taxes, the loss on sale of subsidiaries, earnings attributable to noncontrolling interests and every cash outflow are printed in parentheses and are stored as negative numbers.
• medical_care_ratio_percent is the medical care ratio as printed in the results summary of each filing's Management's Discussion and Analysis, which the company defines as medical costs divided by premium revenue.
• capital_expenditures is the cash flow line "Purchases of property, equipment and capitalized software".
• Computed figures, not printed in the filings: free_cash_flow is cash flows from operating activities less purchases of property, equipment and capitalized software; total_debt is "Short-term borrowings and current maturities of long-term debt" plus "Long-term debt, less current maturities". The trailing-twelve-month block is also computed, as described in that block.
• common_shares_outstanding is the share count on the closing balance rows of the statement of changes in equity, printed in millions. The 10-Q reports that forward share repurchase contracts covering 6.4 million shares bought by a counterparty were settled on July 1, 2026, after the June 30, 2026 balance sheet date.
• cash_dividends_paid_per_share is taken from the statement of changes in equity, which prints it in the caption of the cash dividends row (for example, "Cash dividends paid on common shares ($ 2.32 per share)" for the second quarter of 2026).
• Diluted earnings per share for the second quarter and first six months of 2026 ($6.04 and $12.94) are slightly below net earnings attributable to common shareholders divided by diluted shares. The 10-Q explains that the calculation of basic and diluted earnings per share includes an immaterial reduction to net earnings attributable to common shareholders for undistributed earnings attributable to shares held by the counterparty to its forward share repurchase contracts.
• The 10-Q presents its cash flow statement for the six months ended June 30 only, so the two quarters carry no cash flow block; the six-month cash flows are in year_to_date. The 10-Q prints no June 30, 2025 balance sheet, and the 10-K prints no December 31, 2023 balance sheet, so those periods carry none.
• No stock split, currency translation or depositary-share adjustment applies: the company reports in US dollars, its common stock trades directly on the NYSE, and it has had no stock split in the periods covered.

Uncertainties

• Three-month cash flow figures for the second quarters of 2026 and 2025 are not given here. The 10-Q prints cash flows only for the six-month periods, and the first-quarter figures needed to separate out the second quarter are not in these two filings.
• Weighted-average share counts are printed rounded to the nearest million, so dividing net earnings by them reproduces the printed earnings per share only approximately.

Company details

Fiscal period

Source filings